See What HealthDay Can Do For You
Contact Us

Metformin Tied to Better Clinical Outcomes in CKD, CHF, CLD

Reduced all-cause death for chronic kidney disease, congestive heart failure, chronic liver disease


WEDNESDAY, Jan. 4, 2017 (HealthDay News) -- For patients with chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) with hepatic impairment, metformin use is associated with improvements in clinical outcomes, according to a review published online Jan. 3 in the Annals of Internal Medicine.

Matthew J. Crowley, M.D., from the Durham Veterans Affairs Medical Center and Duke University School of Medicine in North Carolina, and colleagues synthesized data addressing outcomes of metformin use in patients with type 2 diabetes and moderate to severe CKD, CHF, or CLD with hepatic impairment. Data were included from studies that compared diabetes regimens that included metformin with those that did not, and reported all-cause mortality, major adverse cardiovascular events, and other outcomes of interest.

The researchers found that metformin use correlated with reduced all-cause mortality in patients with CKD, CHF, or CLD with hepatic involvement on the basis of quantitative and qualitative syntheses involving 17 observational studies. In patients with CKD or CHF, metformin use correlated with fewer heart failure readmissions.

"Metformin use in patients with moderate CKD, CHF, or CLD with hepatic impairment is associated with improvements in key clinical outcomes," the authors write. "Our findings support the recent changes in metformin labeling."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.